Switzer­land's Fer­ring Phar­ma to build $32M dis­cov­ery, de­vel­op­ment and man­u­fac­tur­ing cen­ter at HQ

Ex­pand­ing its glob­al head­quar­ters in Switzer­land, Fer­ring Phar­ma­ceu­ti­cals is in­vest­ing 30 mil­lion Swiss francs (rough­ly $32 mil­lion) in a new biotech cen­ter.

In ad­di­tion to man­u­fac­tur­ing bi­o­log­ics (in­clud­ing Rekovelle, the lat­est of the com­pa­ny’s many fer­til­i­ty treat­ments), the new fa­cil­i­ty will have dis­cov­ery and de­vel­op­ment ca­pa­bil­i­ties for mon­o­clon­al an­ti­bod­ies.

Fer­ring, a spe­cial­ty phar­ma with a long his­to­ry of mak­ing drugs for women and their ba­bies, al­ready op­er­ate a num­ber pro­duc­tion fa­cil­i­ties around the globe, with pro­duc­tion fa­cil­i­ties from Ar­genti­na to Den­mark to In­dia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA